Khalil 2006a.

Methods	Study design: RCT Study duration: 2 years Study follow‐up: 48 hours
Participants	Country: UK Setting: single centre Inclusion criteria: elective coronary artery bypass grafting Number: treatment group (21); control group (19) Mean age ± SD (years): treatment group (56.7 ± 9.1); control group (58.8 ± 6.6) Sex (M/F): not reported Exclusion criteria: diabetics; on anticoagulants; previous cerebrovascular disease
Interventions	Treatment group Parecoxib: single IV dose of 40 mg given at closure of sternotomy Control group Placebo: single IV dose given at closure of sternotomy
Outcomes	24 hour urinary CrCl, urinary a‐1‐microglobulin
Notes	Funding: Pharmacia Furosemide given in post‐operative phase for oliguria; (treatment 12/21 patients, control 9/19 patients)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerised randomisation using a number generator
Allocation concealment (selection bias)	Low risk	A third party placed the results of the randomisation in sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Envelopes were opened at close of the surgery and a third party prepared the study medication (placebo or treatment) which looked identical
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Initial power calculations resulted in an intended study population size of 60 patients. Following a global announcement of Pfizer that parecoxib was ‘contraindicated in patients with ischaemic heart disease’ further inclusion in the study was terminated at 40. Data of all 40 patients is presented
Selective reporting (reporting bias)	Low risk	Study protocol matches outcomes presented
Other bias	High risk	Commercial funding source Pharmacia, which is the manufacturer of Parecoxib